Opidivo research detailed at European Hematology conference
Opdivo contains nivolumab, and data from this trial was featured during the European Hematology Association Congress (EHA) that took place in Copenhagen this week.
Participants that responded with the medicine reported median remission times that averaged 7.8 months. Participants of this study consisted of classical Hodgkin lymphoma. The company also noted that the safety profile for Opdivo was consistent with prior studies regarding this kind of tumor.
“Classical Hodgkin lymphoma is a disease that disproportionately impacts young people, and there is a significant unmet need for patients who are not cured by the current standard-of-care treatments and who have a poor prognosis and very limited options,” Oncological Global Clinical Research Lead Dr. Jean Viallet said. “The data presented at EHA demonstrate that Opdivo is an important treatment option for patients whose disease has progressed after auto-HSCT and post-transplantation brentuximab vedotin.”
The drug received a U.S. Food and Drug Administration approval in hematology in May.
“We are encouraged by the objective response rates and that the majority of responses were ongoing at the time of analysis in the CheckMate - 205 trial evaluating Opdivo in these heavily pre-treated patients,” Lead Investigator and Professor of Internal Medicine, Hematology and Oncology at the University Hospital of Cologne, Germany, Dr. Andreas Engert said.